Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.80 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.80 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.80 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16585703 | 0.98 | HTR1A (0.77) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL9850466 | 0.84 | HTR1A (0.89) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL18290254 | 0.84 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL22390094 | 0.84 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL15929304 | 0.84 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL31197367 | 0.84 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL18095970 | 0.83 | HTR1A (0.80) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL6698838 | 0.83 | FERMT2 (1.00) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL9591573 | 0.83 | HTR1A (0.80) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL8909254 | 0.83 | HTR1A (0.80) | HTR1AADRA1DADRA1AADRA1BFERMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450299-B2 | Substituted quinazoline derivatives as DNA methyltransferase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-10-22 | — | — | US | disclosed |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-05-03 | — | — | US | disclosed |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-05-03 | — | — | US | disclosed |
| US-9951044-B2 | Quinazoline derivatives and their use as DNA methyltransferase inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2018-04-24 | — | — | US | disclosed |
| US-9951044-B2 | Quinazoline derivatives and their use as DNA methyltransferase inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2018-04-24 | — | — | US | disclosed |
| EP-3046917-B1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PF MEDICAMENT (FR) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016151144-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-09-29 | — | — | WO | disclosed |
| US-20160229834-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-08-11 | — | — | US | disclosed |
| US-20160229834-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-08-11 | — | — | US | disclosed |
| WO-2015040169-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2015-03-26 | — | — | WO | disclosed |
| US-8952016-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450299-B2 | Substituted quinazoline derivatives as DNA methyltransferase inhibitors | DNMT1, DNMT3A, DNMT3B | HTR1A 2853/4885ADRA1D 3223/4885ADRA1A 2917/4885 |
| US-20160229834-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | DNMT1, DNMT3A, TPMT | HTR1A 2733/4885ADRA1D 3354/4885ADRA1A 3039/4885 |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | DNMT1, DNMT3A, DNMT3B | HTR1A 2853/4885ADRA1D 3223/4885ADRA1A 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.